Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes

Werner, Nikos; Kosiol, Sonja; Schiegl, Tobias

doi:10.1016/j.accreview.2005.11.011

Cited by 172 publications

(267 citation statements)

References 36 publications

Supporting

Mentioning

236

Contrasting

Unclassified

Order By: Relevance

“…in this study clearly indicated that increased levels of CD34 + /VEGFR2 + EPCs and EPC CFUs were accompanied by decreasing risk of death from cardiovascular cause, revascularization, hospitalization, and the occurrence of a first major cardiovascular event. These findings suggest that the level of PB EPCs may serve as an indicator of cardiovascular outcome in patients with CAD [62].…”

Section: Cardiovascular Diseasesmentioning

confidence: 92%

See 1 more Smart Citation

Endothelial progenitor cells as a new agent contributing to vascular repair

Miller-Kasprzak

Jagodzińśki

2007

Arch. Immunol. Ther. Exp.

117

View full text Add to dashboard Cite

A special type of stem cells, defined as endothelial progenitor cells (EPCs), has been found in the bone marrow and peripheral blood. These EPCs are incorporated into injured vessels and become mature endothelial cells during re-endothelialization and neovascularization processes. Though a complete phenotypic description of EPCs remains unclear, these cells express several surface markers, the most relevant including CD34 and CD133 antigens. Furthermore, EPCs derived from other sources could also give rise to mature endothelial cells, which makes this group of cells more diverse. The recruitment of EPCs from the bone marrow to homing sites of vasculogenesis is subject to regulation by many factors, including chemokines and growth factors. The precise mechanism of EPC mobilization and differentiation is not entirely elucidated and is still under investigation. Recent studies have suggested that EPCs may promote local angiogenesis by secreting angiogenic growth factors in a paracrine manner. The number and function of EPCs can be affected during pathological conditions, including diabetes mellitus, cardiovascular risk factors for ischemic disease, and graft vasculopathy. Additionally, EPC number and migration capacity could be improved by such factors as drugs, physical exercise, and growth factors. Transplantation of EPCs into ischemic tissues may emerge as a promising approach in the therapy of diseases associated with blood vessel disorders.

show abstract

Section: Cardiovascular Diseasesmentioning

confidence: 92%

“…A recent report by Werner et al [62] concerned the relationship between EPC level and the occurrence of vascular events in patients with CAD. Results obtained [23] as CD133 + , CD34 + , and VEGFR2 + angioblasts [23,58].…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Endothelial progenitor cells as a new agent contributing to vascular repair

Miller-Kasprzak

Jagodzińśki

2007

Arch. Immunol. Ther. Exp.

117

View full text Add to dashboard Cite

show abstract

“…The level of circulating CD34 + KDR + EPCs predicted the occurrence of cardiovascular events and death from cardiovascular causes in our study population [23]. Compared to preclinical studies performed in rodent models clinical trials have not been as efficacious as predicted [26,27].…”

Section: Epc Phenotypes/putative Endothelial Progenitor Cell Populationsmentioning

confidence: 97%

“…The majority of clinical trials of human cell therapy for various forms of ischemic vascular disease have relied on autologous bone marrow-derived, CD34 + /KDR + and CD133 + cells that have displayed modest regenerative and reparative roles [23,24,25]. The level of circulating CD34 + KDR + EPCs predicted the occurrence of cardiovascular events and death from cardiovascular causes in our study population [23].…”

Section: Epc Phenotypes/putative Endothelial Progenitor Cell Populationsmentioning

confidence: 98%

Regeneration of the vascular compartment

Becher

Nickenig

Werner

2010

Herz

Self Cite

View full text Add to dashboard Cite

Throughout life, damage to the vascular endothelium is pivotal in the development of cardiovascular disease. Therefore, a detailed understanding of the underlying mechanisms involved in endothelial cell restoration is of fundamental importance for preventive and therapeutic concepts in cardiovascular disease. The goal of regenerative medicine is the use of tissue-specific progenitor cells for a more effective repair process with reduction of fibrocellular remodelling, fibrosis and loss of functional properties.According to the hitherto assumed primary model of endothelial regeneration only adjacent and intact mature endothelial cells replace damaged endothelium. Since Asahara and colleagues first described that a peripheral blood mononuclear cell population was able to differentiate into endothelial cells in vitro and incorporate into ischemic tissue at sites of angiogenesis in vivo, the model of endothelial regeneration has been extended. The majority of clinical trials on human cell therapy for ischemic vascular disease are based on cell surface antigen expression of CD34 or VEGFR2 to identify endothelial progenitor cells.A precise characterization of the angiogenic properties of different subsets of endothelial regenerating cells and their course of action to gain sufficient long-term regeneration of the injured vessel is a necessary precondition before clinical trials of human cell therapy become a routine reality.

show abstract

“…In Tiermodellen, aber auch in klinischen Studien konnte diesbezüglich gezeigt werden, dass zirkulierende endotheliale Progenitorzellen (EPCs) z.T. für diese endothelialen Reparaturmechanismen verantwortlich sind und mit dem Risiko kardiovaskulärer Ereignisse korrelieren [19,20]. Entsprechend der Assoziation der endothelialen und erektilen Funktion konnte eine hochsignifikante Korre lation der Anzahl von EPCs mit der Erektionsfähigkeit nachgewiesen werden [21].…”

Section: Zusammenfassungunclassified

Erektile Dysfunktion: Indikator für Endorganschädigung beim kardiovaskulären Patienten

Baumhäkel

Schlimmer²,

Kratz³

et al. 2009

Med Klin

View full text Add to dashboard Cite

Prevalence of erectile dysfunction (ED) amounts to 20-30% in a general population and increases to 50-70% in cardiovascular high-risk patients. Association of ED with known cardiovascular risk factors is causal with endothelial function of penile vessels and corpora cavernosa playing a crucial role in physiology of erection. Moreover, severity of ED correlates with cardiovascular risk of patients and represents an early symptom of generalized atherosclerosis. Hence, cardiovascular risk factors and diseases are sooner diagnosed in patients with ED with the opportunity of risk-adjusted prevention. Furthermore, different trials suggest erectile function as a strong predictor of cardiovascular events like myocardial infarction or stroke.

show abstract

Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes

Cited by 172 publications

References 36 publications

Endothelial progenitor cells as a new agent contributing to vascular repair

Endothelial progenitor cells as a new agent contributing to vascular repair

Regeneration of the vascular compartment

Erektile Dysfunktion: Indikator für Endorganschädigung beim kardiovaskulären Patienten

Contact Info

Product

Resources

About